Foundation-model-guided radiogenomic discovery linking cancer genomes to cancer scans

Lung cancer remains one of the leading causes of cancer- related mortality worldwide. Although targeted therapies have improved outcomes for patients with non-small cell lung cancer (NSCLC), they rely on mutation profiling through tissue biopsy, an invasive procedure with several limitations. This study investigates PET/CT-based radio- genomic prediction of epidermal growth factor receptor (EGFR), tumour protein 53 (TP53), and Kirsten rat sarcoma viral oncogene (KRAS) mutations using deep learning. We further evaluate whether pairwise multi-label learning improves mutation prediction compared with conventional single-gene classification. To the best of our knowledge, this is among the first studies to systematically investigate multi-label learning for PET/CT radiogenomic mutation prediction in NSCLC. Experiments were conducted on a novel UK-based radiogenomics cohort. Joint pre- diction of KRAS and TP53 improved AUC from 0.58 to 0.64 for KRAS and from 0.69 to 0.71 for TP53. For the EGFR/KRAS pair, only EGFR benefited from joint learning, while no improvement was observed for the EGFR/TP53 pair. These findings demonstrate that the effectiveness of multi-label learning depends on the specific combination of gene mutations being modelled, suggesting that mutation-specific modelling strategies may be preferable for PET/CT radiogenomic prediction.

Background: Radiogenomics allows identification of radiological biomarkers for genomic phenotypes. In glioblastoma, these biomarkers could potentially complement patient stratification strategies. We aim to develop and analytically validate radiological biomarkers that capture immune cell signatures within IDH-wildtype glioblastoma microenvironment using radiogenomic analysis. Methods: This was a retrospective multicenter study using curated open-access anonymized imaging and genomic data from TCGA-GBM, CPTAC, IvyGAP, REMBRANDT and CGGA datasets. Imaging data consisted of MRI-based radiomic features extracted from necrotic core, enhancing and edema regions of deep learning-based auto-segmented tumors. Radiomic feature selections were performed using nested cross-validated LASSO. Support vector machine and ensemble models were trained using seventeen immune and cell-specific score labels extracted from deconvoluted transcriptomic data using pan-cancer and glioblastoma immune signature matrices as reference standards. Seventeen classifier models trained in three cross-cohort strategies were validated on three held-out datasets assessing stability and generalizability. Results: One-hundred-and-seventy-six patients were included in the study. The immune-related radiomic signatures obtained after feature selection were shape, first order and higher order radiomic features. Models predicting macrophage subtype immune signature showed stable mean performance on balanced accuracy (0.67) and precision (0.89) metrics for three independent holdout datasets with ensemble model outperforming support vector machine model. Conclusion: Radiogenomic models non-invasively predicted the macrophage subtype M0 immune signature in IDH-wildtype glioblastoma. These biomarkers have the potential to stratify patients for immunotherapy within prospective glioblastoma clinical trials.

Pathology foundation models are reported to encode molecular programmes in tissue morphology, but the evidence is usually a cohort-wide ranked gene list rather than a prediction for a held-out patient. We rebuild such an analysis with the patient as the unit of evidence and ask which pipeline component carries signal. Across 11 frozen backbones, four pre-specified gene programmes and 285 TCGA-BRCA patients with paired slides and RNA-seq (44 cells; GroupKFold by patient, all preprocessing fitted inside the fold), ridge regression on mean-pooled embeddings predicts held-out programme scores at Spearman rho = 0.25-0.56, UNI2 strongest on all four (immune 0.556). A matched permutation null gives raw p ~ 1e-4 at 10,000 permutations for every cell; Holm-adjusted p = 0.0044. The signal is real but not uniformly morphological. Against competing models on the same patients and folds, embeddings beat tissue composition for ER/luminal, proliferation and immune (+0.280, +0.284, +0.479; p <= 0.003) but not basal, where compartment fractions alone reach 0.469 against the embedding's 0.493 (p = 0.77). Fifty-four interpretable cell-count features come within 0.043-0.085 on every programme. The geometric machinery contributes nothing measurable, and we identify why: the geodesic graph selects neighbours by Euclidean nearest-neighbour search and only reweights edges already chosen, so the topology is Euclidean by construction (Riemannian minus Euclidean = +0.0010, 95% CI [-0.0007, +0.0029]). Applied consistently the geometry is worse (-0.0117). Ridge regression beats the graph-and-metric decoder by +0.097 (CI [+0.069, +0.127]). The driver-count metric common in this literature is near-uninformative here: 91.8% of random six-gene panels recover >=5/6 drivers.